Efficacy of add-on adefovir dipivoxil at week 12/24 in HBeAg-positive chronic hepatitis B patients during PEG-IFNα therapy

Efficacy of add-on adefovir dipivoxil at week 12/24 in HBeAg-positive chronic hepatitis B patients during PEG-IFNα therapy

ObjectiveTo investigate the efficacy of add-on adefovir dipivoxil (ADV) at week 12/24 in HBeAg-positive chronic hepatitis B (CHB) patients with hepatitis B virus (HBV) DNA levels of ≥105 copies/ml during pegylated interferonα (PEG-IFNα) therapy. MethodsA retrospective analysis was performed on 74 HB...

Full description

Bibliographic Details
Main Authors:	YOU Jia, CHEN Jing, YE Qiaoxia
Format:	Article
Language:	zho
Published:	Editorial Department of Journal of Clinical Hepatology 2016-04-01
Series:	Linchuang Gandanbing Zazhi
Online Access:	http://www.lcgdbzz.org/qk_content.asp?id=7296

Similar Items

Influence of combination mode of PEG-IFNα-2a and adefovir dipivoxil on outcome of patients with HBeAg-positive chronic hepatitis B
by: WU Xioali
Published: (2017-12-01)

Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B
by: MA Yanhong
Published: (2013-08-01)

Long-term therapy with adefovir dipivoxil for HBeAg positive chronic hepatitis B patients with various baseline biochemical levels: Results from 4 years adefovir dipivoxil treatment
by: L. Zhuang, et al.
Published: (2014-04-01)

Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B
by: HUANG Meijin
Published: (2014-07-01)

Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B: preliminary comparative study
by: YAN Haiming
Published: (2013-07-01)

The Change of Quantitative of HBeAg Can Predict the Efficacy of Peg-IFN-α 2a in HBeAgpositive CHB Patients
by: Ji Yong-jian, et al.
Published: (2013-09-01)

Adefovir Dipivoxil
by: Francisco Javier Hevia-Urrutia
Published: (2008-11-01)

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks
by: Xiaomei Wang, et al.
Published: (2020-10-01)

Study of hepatic histomorphology in HBeAg+ and HBeAg− patients with CHB: Experience from Bangladesh
by: Ayub Al Mamun, et al.
Published: (2013-01-01)

The effect of patients with chronic hepatitis B HBeAg（+）with poor response to treatment by converting to sequential treatment with tenofovir dipivoxil
by: Zhi-Xiong Liao
Published: (2020-03-01)

Association between IPS-1 polymorphisms and PEG-IFN treatment response in patients with HBeAg-positive chronic hepatitis B
by: WU Haiqing
Published: (2014-08-01)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
Published: (2006-01-01)

HBeAg-negative chronic hepatitis
by: M M Ibragimova, et al.
Published: (2004-02-01)

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α
by: Hu Yao-ren, et al.
Published: (2014-03-01)

A Study on Adefovir Dipivoxil Pills
by: Yi-Jou Chou, et al.
Published: (2008)

Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B.
by: Thilde Nordmann Winther, et al.
Published: (2013-01-01)

52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
by: Teerha Piratvisuth, et al.
Published: (2013-01-01)

Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion.
by: Yen-Ling Ko, et al.
Published: (2015-01-01)

Relationship of T Cell Immunity and HBeAg Loss During Telbivudine Treatment in Patients with HBeAg-positive Chronic Hepatitis B
by: Yih-Tsong Shiau, et al.
Published: (2014)

Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis
by: Zhao Jun, et al.
Published: (2011-02-01)

Significance of changes in hepatic histology from patients with HBeAg(+) or HBeAg(-) chronic hepatitis B and normal or mildly elevated alanine aminotransferase
by: LAN Lin
Published: (2015-04-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Spectrophotometric Determination of Adefovir Dipivoxil in bulk and Pharmaceutical Formulation
by: Zaheer Ahmed, et al.
Published: (2008-01-01)

Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
by: Chao-Wei Hsu, et al.
Published: (2018-07-01)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
by: Emilia Hadziyannis, et al.
Published: (2018-09-01)

Develop genetic programming to predict the state of seroconversion of HBeAg
by: Chu-Yu Chin, et al.
Published: (2005)

Influence of quantitative changes in HBeAg on the therapeutic efficacy of antiviral drugs
by: XIE Zhiwei
Published: (2013-02-01)

Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy.
by: Hwi Young Kim, et al.
Published: (2012-01-01)

Fanconi syndrome with hypophosphatemic osteomalacia induced by low-dose adefovir dipivoxil
by: WANG Shouqing, et al.
Published: (2016-01-01)

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients.
by: Junfeng Lu, et al.
Published: (2015-01-01)

Lamivudine therapy in HBeAg negative chronic hepatitis B patients
by: E. Guclu, et al.
Published: (2014-04-01)

The Prediction of HBeAg Seroconversion and DNA Sequence Mutation Rate of HBV
by: Wei-Liang Liu, et al.
Published: (2006)

Clinical effect of 24-week TDF versus ADV sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to 48-week pegylated interferon-α-2a treatment
by: LYU Ying, et al.
Published: (2016-11-01)

Possible immunochemical pattern of anti-HCV, HBeAg, HBsAg HBeAb, and HIV-1 p24 in newly infected Mycobacterium pulmonary tuberculosis patients
by: Mathew Folaranmi Olaniyan, et al.
Published: (2019-01-01)

The Effects of HBcAg and HBeAg on the Expression of Cytokine Genes from Murine Macrophages
by: Kung-yen Chang, et al.
Published: (1999)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
by: Byung-Cheol Song, et al.
Published: (2014-12-01)

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.
by: Tongjing Xing, et al.
Published: (2017-01-01)

Clinical analysis of hypophosphatemia induced by adefovir dipivoxil in treatment of chronic hepatitis B
by: YANG Xiaoyan, et al.
Published: (2015-12-01)

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia
by: Flamir da Silva Victoria, et al.

Host Factors on Spontaneous HBeAg Seroconversion in Chronic HBV Infected Patients
by: Jia-Feng Wu, et al.
Published: (2010)